302 related articles for article (PubMed ID: 24244338)
1. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
Chow AK; Ng L; Lam CS; Wong SK; Wan TM; Cheng NS; Yau TC; Poon RT; Pang RW
PLoS One; 2013; 8(11):e78675. PubMed ID: 24244338
[TBL] [Abstract][Full Text] [Related]
2. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
3. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
4. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
6. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
7. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
10. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
Wang H; Qian Z; Zhao H; Zhang X; Che S; Zhang H; Shang H; Bao J; Hao C; Liu J; Li Z
Mol Med Rep; 2015 Sep; 12(3):3902-3908. PubMed ID: 26035694
[TBL] [Abstract][Full Text] [Related]
11. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
[TBL] [Abstract][Full Text] [Related]
12. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
15. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
Xu Y; Xu H; Li M; Wu H; Guo Y; Chen J; Shan J; Chen X; Shen J; Ma Q; Liu J; Wang M; Zhao W; Hong J; Qi Y; Yao C; Zhang Q; Yang Z; Qian C; Li J
Cancer Lett; 2019 Jul; 454():78-89. PubMed ID: 30980868
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
Liu J; Cui X; Qu L; Hua L; Wu M; Shen Z; Lu C; Ni R
Exp Mol Pathol; 2016 Aug; 101(1):58-65. PubMed ID: 27302463
[TBL] [Abstract][Full Text] [Related]
17. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852
[TBL] [Abstract][Full Text] [Related]
18. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
19. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Huang WC; Hsieh YL; Hung CM; Chien PH; Chien YF; Chen LC; Tu CY; Chen CH; Hsu SC; Lin YM; Chen YJ
PLoS One; 2013; 8(12):e83627. PubMed ID: 24391798
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
